Clinical Trial Update: A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed sorafenib alone and in combination with low-dose interferon in patients with advanced renal cell carcinoma that progressed after suniti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon alfa-2b (interferon alfa-2b)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: TERMINATED | Results posted: 2010-10-01